Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Antineoplastic, pyrimidine analogue (5-FU)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. Liver enzymes, mainly CYP2C9, metabolise it. According to the Spanish generic acenocoumarol summary of product characteristics (SmPC), CYP2C9 inhibitors can potentiate its anticoagulant effect (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In a small number of patients stabilised on warfarin, marked rises in the prothrombin time and the international normalised ratio (INR) have been reported after fluorouracil was started. The Spanish fluorouracil SmPC extends regular monitoring of the anticoagulant response to other coumarin anticoagulants, and acenocoumarol is one of them (fluorouracil and acenocoumarol SmPCs, AEMPS). The documents do not describe the mechanism for this pair. For phenytoin, which CYP2C9 also metabolises, the fluorouracil SmPC presumes that fluorouracil inhibits CYP2C9 or CYP2C19. No formal interaction studies have been done (fluorouracil SmPC, AEMPS). According to the US fluorouracil label, altered coagulation parameters and bleeding, including deaths, have been reported with warfarin. The documents contain no study with acenocoumarol (fluorouracil prescribing information, US Food and Drug Administration, FDA).

Symptoms

The main risk is bleeding. After fluorouracil was started, marked rises in the prothrombin time and the international normalised ratio (INR) have been reported in patients stabilised on warfarin (fluorouracil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label reports bleeding with this combination, including fatal cases (fluorouracil prescribing information, US Food and Drug Administration, FDA). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cancer is one of the risk factors for bleeding during acenocoumarol treatment (acenocoumarol SmPC, AEMPS). Fluorouracil itself can cause bone marrow suppression, including thrombocytopenia, and gastrointestinal bleeding (fluorouracil SmPC, AEMPS).

Management

The combination is not contraindicated but needs regular coagulation monitoring. Monitor the response to coumarin anticoagulants regularly in patients receiving fluorouracil (fluorouracil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC asks for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPC, AEMPS). For warfarin, the US fluorouracil label asks for more frequent international normalised ratio (INR) checks and warfarin dose adjustment, including after fluorouracil is stopped (fluorouracil prescribing information, US Food and Drug Administration, FDA). During fluorouracil treatment, the SmPC recommends daily platelet and white cell counts. Stop fluorouracil if platelets fall below 100,000/mm³ and at the first sign of gastrointestinal bleeding or bleeding at any site (fluorouracil SmPC, AEMPS). Acenocoumarol is contraindicated with a platelet count below 50×10⁹/L (acenocoumarol SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Fluorouracil